Prothena Corporation plc Logo

Email this page: News Release

Prothena Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases

For security reasons, registration is required before you can use this feature.
* Indicates required field